From #EASD2026 - Prof. Elif Ekinci shares the efficacy and safety findings from TRIUMPH-2, a phase 3 trial of the GIP, GLP-1, and glucagon receptor agonist #retatrutide in patients with type 2 diabetes and obesity.
Watch the full interview 👉️ buff.ly/sivRg5m
#DiabetesCare
From #EASD2026 - Prof. Elif Ekinci shares the efficacy and safety findings from TRIUMPH-2, a phase 3 trial of the GIP, GLP-1, and glucagon receptor agonist #retatrutide in patients with type 2 diabetes and obesity. Watch the full interview 👉️ buff.ly/sivRg5m #DiabetesCare
0 vue
Publié le 15/10/2026 10:54
0:36
From #EASD2026 - Prof. Elif Ekinci shares the efficacy and safety findings from TRIUMPH-2, a phase 3 trial of the GIP, GLP-1, and glucagon receptor agonist #retatrutide in patients with type 2 diabetes and obesity.
Watch the full interview 👉️ buff.ly/sivRg5m
#DiabetesCare
0 commentaire
?